CARDIOVASCULAR JOURNAL OF AFRICA • Vol 23, No 7, August 2012
AFRICA
395
Lancet
2008;
371
(9616): 915–922.
8.
Sliwa K, Carrington MJ, Becker A, Thienemann F, Ntsekhe M, Stewart
S. Contribution of the human immunodeficiency virus/acquired immu-
nodeficiency syndrome epidemic to de novo presentations of heart
disease in the Heart of Soweto Study cohort.
Eur Heart J
2011:
33
(7);
866–874.
9.
Norman R, Bradshaw D, Steyn K, Gaziano T. Estimating the burden of
disease attributable to high cholesterol in South Africa in 2000.
S Afr
Med J
2007;
97
(8 Pt 2): 708–715.
10. Njelekela MA, Mpembeni R, Muhihi A, Mligiliche NL, Spiegelman
D, Hertzmark E,
et al.
Gender-related differences in the prevalence
of cardiovascular disease risk factors and their correlates in urban
Tanzania.
BMC Cardiovasc Disord
2009;
9
: 30.
11. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R,
et
al.
European guidelines on cardiovascular disease prevention in clinical
practice: executive summary: Fourth Joint Task Force of the European
Society of Cardiology and Other Societies on Cardiovascular Disease
Prevention in Clinical Practice (Constituted by representatives of nine
societies and by invited experts).
Eur Heart J
2007;
28
(19): 2375–2414.
12. Butler N. National Guidelines at a glance: Hypercholesterolaemia.
SA
Pharmaceut J
2009;
76
(6): 28–33.
13. Third Report of the National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
Circulation
2002;
106
(25): 3143–3421.
14. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO,
3rd, Criqui M,
et al
. Markers of inflammation and cardiovascular
disease: application to clinical and public health practice: A statement
for healthcare professionals from the Centers for Disease Control and
Prevention and the American Heart Association.
Circulation
2003;
107
(3): 499–511.
15. Civeira F. Guidelines for the diagnosis and management of heterozy-
gous familial hypercholesterolemia.
Atherosclerosis
2004;
173
(1):
55–68.
16. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J,
Catapano AL,
et al
. Triglyceride-rich lipoproteins and high-density
lipoprotein cholesterol in patients at high risk of cardiovascular disease:
evidence and guidance for management.
Eur Heart J
2011;
32
(11):
1345–1361.
17. Maritz FJ.
Dyslipidaemia in South Africa
. Cape Town: South African
Medical Research Council 2006.
18. Steyn K, Sliwa K, Hawken S, Commerford P, Onen C, Damasceno A,
et al.
Risk factors associated with myocardial infarction in Africa: the
INTERHEART Africa study.
Circulation
2005;
112
(23): 3554–3561.
19. Seftel HC, Asvat MS, Joffe BI, Raal FJ, Panz VR, Vermaak WJ,
et al.
Selected risk factors for coronary heart disease in male scholars from
the major South African population groups.
S Afr Med J
1993;
83
(12):
891–897.
20. Truswell AS, Mann JI. Epidemiology of serum lipids in Southern
Africa.
Atherosclerosis
1972;
16
(1): 15–29.
21. Oelofse A, Jooste PL, Steyn K, Badenhorst CJ, Lombard C, Bourne L,
et al
. The lipid and lipoprotein profile of the urban black South Africa
population of the Cape Peninsula – the BRISK study.
S Afr Med J
1996;
86
(2): 162–166.
22. Walker AR, Walker BF. High high-density-lipoprotein cholesterol in
African children and adults in a population free of coronary heart
diseae.
Br Med J
1978;
2
(6148): 1336–1337.
23. Kruger HS, Puoane T, Senekal M, van der Merwe MT. Obesity in South
Africa: challenges for government and health professionals.
Public
Health Nutr
2005;
8
(5): 491–500.
24. De Villiers WJ, van der Westhuyzen DR, Coetzee GA, Henderson
HE, Marais AD. The apolipoprotein E2 (Arg145Cys) mutation causes
autosomal dominant type III hyperlipoproteinemia with incomplete
penetrance.
Arterioscler Thromb Vasc Biol
1997;
17
(5): 865–872.
25. Vorster HH. The emergence of cardiovascular disease during urbanisa-
tion of Africans.
Public Health Nutr
2002;
5
(1A): 239–243.
26. Steyn K, Kazenellenbogen JM, Lombard CJ, Bourne LT. Urbanization
and the risk for chronic diseases of lifestyle in the black population
of the Cape Peninsula, South Africa
. J Cardiovasc Risk
1997;
4
(2):
135–142.
27. Pearson TA. Education and income: double-edged swords in the epide-
miologic transition of cardiovascular disease.
Ethn Dis
2003;
13
(2
Suppl 2): S158–163.
28. Ubbink JB, Vermaak WJ, Delport R, van der Merwe A, Becker PJ,
Potgieter H. Effective homocysteine metabolism may protect South
African blacks against coronary heart disease.
Am J Clin Nutr
1995;
62
(4): 802–808.
29. Goodman AH. Why genes don’t count (for racial differences in health).
Am J Public Health
2000;
90
(11): 1699–1702.
30. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of
diabetes for 2010 and 2030.
Diabetes Res Clin Pract
2010;
87
(1): 4–14.
